Form 4: Apellis Pharmaceuticals General Counsel Reports Scheduled Stock Sale Under 10b5-1 Plan

Apellis Pharmaceuticals' General Counsel, David O. Watson, filed a Form 4 disclosing the sale of 5,000 shares of common stock at $18.77 per share, executed as part of a pre-established 10b5-1 trading plan.

Summary

• David O. Watson, General Counsel of Apellis Pharmaceuticals, Inc. (APLS), filed a Form 4 with the SEC.
• The filing reports the sale of 5,000 shares of Apellis Pharmaceuticals Common Stock.
• The transaction occurred on June 16, 2025.
• The shares were sold at a price of $18.77 per share.
• This sale was conducted pursuant to a pre-established Rule 10b5-1 trading plan, which allows insiders to sell shares at a predetermined time or price to avoid accusations of trading on material non-public information.
• Following this transaction, Mr. Watson directly beneficially owns 133,730 shares of common stock.
• Additionally, 10,000 shares are held indirectly in a custodial account for his minor children, and 70,136 shares are held indirectly by The David O. Watson Irrevocable Trust of 2023.

Sentiment

Score: 5

Explanation: A Form 4 filing for a scheduled sale under a 10b5-1 plan is generally neutral. It reflects an insider's pre-planned liquidity management rather than a reaction to new company performance or strategic shifts, and thus has minimal direct impact on company sentiment.

Future Outlook

This document does not provide any forward-looking statements or guidance regarding the company's future performance or strategic outlook. It solely reports a past insider transaction.

Management Comments

• "This is a scheduled sale from an established 10B5-1 trading plan."
• "The reporting person disclaims beneficial ownership over the shares held by The David O. Watson Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein."

Industry Context

Form 4 filings are routine disclosures for corporate insiders reporting changes in their beneficial ownership of company securities. The use of a Rule 10b5-1 trading plan for such sales is a common and accepted practice across all industries, allowing executives to manage personal liquidity or diversify holdings in a manner compliant with SEC regulations, mitigating concerns about trading on non-public information.

Comparison to Industry Standards

• The filing of a Form 4 for an insider stock transaction is a standard regulatory requirement for publicly traded companies in the U.S., consistent with practices across all industries.
• The execution of the sale under a Rule 10b5-1 trading plan aligns with best practices for corporate insiders to manage their equity holdings transparently and in compliance with insider trading laws, a common approach seen in companies comparable to Apellis Pharmaceuticals.

Stakeholder Impact

• Shareholders: The sale by a General Counsel, even if pre-planned, might be viewed by some as a routine liquidity event, while others might interpret any insider sale as a slight negative signal, though the 10b5-1 plan mitigates concerns about trading on non-public information.

Key Dates

Keywords

Apellis Pharmaceuticals, APLS, Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, David O. Watson, General Counsel, Equity Transaction, SEC Filing